GOLDMAN SACHS GROUP INC - ZENTALIS PHARMACEUTICALS INC ownership

ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 133 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.33 and the average weighting 0.4%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of ZENTALIS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$4,478,615
-78.4%
223,261
-69.6%
0.00%
-75.0%
Q2 2023$20,694,208
+489.9%
733,577
+259.7%
0.00%
+300.0%
Q1 2023$3,507,871
-55.4%
203,946
-47.8%
0.00%
-50.0%
Q4 2022$7,862,294
+7.3%
390,382
+15.4%
0.00%0.0%
Q3 2022$7,329,000
-34.4%
338,332
-14.9%
0.00%
-33.3%
Q2 2022$11,171,000
-8.7%
397,570
+49.9%
0.00%0.0%
Q1 2022$12,238,000
+3.0%
265,246
+87.6%
0.00%
+50.0%
Q4 2021$11,883,000
-22.6%
141,369
-38.6%
0.00%
-33.3%
Q3 2021$15,350,000
+242.3%
230,341
+173.3%
0.00%
+200.0%
Q2 2021$4,484,000
+99.5%
84,289
+62.7%
0.00%0.0%
Q1 2021$2,248,000
-80.7%
51,809
-76.9%
0.00%
-66.7%
Q4 2020$11,633,000
+1005.8%
223,983
+596.2%
0.00%
Q3 2020$1,052,000
+58.4%
32,171
+132.8%
0.00%
Q2 2020$664,00013,8200.00%
Other shareholders
ZENTALIS PHARMACEUTICALS INC shareholders Q2 2023
NameSharesValueWeighting ↓
Decheng Capital Management III (Cayman), LLC 2,099,583$42,117,63514.06%
Mayo Clinic 187,143$3,754,0897.23%
Matrix Capital Management Company, LP 13,959,973$280,037,0583.36%
5AM Venture Management, LLC 490,000$9,829,4002.83%
Eventide Asset Management 7,814,039$156,749,6222.82%
TYBOURNE CAPITAL MANAGEMENT (HK) LTD 961,486$19,287,4102.70%
Avidity Partners Management LP 2,100,000$42,126,0001.70%
First Light Asset Management, LLC 848,477$17,020,4491.62%
Sofinnova Investments, Inc. 1,211,641$24,305,5181.53%
SECTORAL ASSET MANAGEMENT INC 386,525$7,753,6921.51%
View complete list of ZENTALIS PHARMACEUTICALS INC shareholders